Nevertheless, baseline NLR was still prognostically independent of MGMT promoter methylation status (58, 129), IDH mutation status (51, 92, 121), and steroid use (122, 124) in patients with glioblastoma, and patients with increased NLR and requiring steroids had the poorest outcomes (73). This evidence concerns the gene IDH1 and glioblastoma.